Janssen Reports Submission of Ponesimod’s MAA to EMA for the Treatment of Relapsing Multiple Sclerosis
Shots:
- The MAA is based on P-III OPTIMUM study assessing Ponesimod (20mg) vs Teriflunomide (14 mg) in patients with RMS
- The P-III OPTIMUM study results: @108wks. 30.5% reduction in ARR; 56% reduction CUALs in the brain; reduction in fatigue symptoms; safety profile is consistent with the previous studies
- Ponesimod is an investigational S1P1 modulator, act by inhibiting S1P activity leading to a reduction in the number of circulating lymphocytes crossing the BBB
Click here to read full press release/ article | Ref: J&J | Image: Janssen